Corcept Therapeutics CORT 深 沪
等待开盘 11-13 09:30:00 美东时间
78.645
-0.365
-0.46%
华盛通- 最 高79.89
- 今 开79.29
- 成交量 12.09万股
- 最 低 78.445
- 昨 收 79.01
- 总市值 82.58亿
- 52周最高 117.33
- 市盈率 静 63.87
- 换手率 0.12%
- 52周最低 49.00
- 委 比 6.32%
- 总股本 1.05亿
- 历史最高 117.33
- 量 比 0.37
- 振 幅 1.83%
- 历史最低 1.27
- 每 手 1
- 风险率 9.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Corcept Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results and cut its FY25 sales guidance below estimates.
Corcept Therapeutics shares are trading lower after the company reported worse-...
11-05 05:43
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Uncovering Potential: Axsome Therapeutics's Earnings Preview
Axsome Therapeutics (NASDAQ:AXSM) is set to give its latest quarterly earnings ...
11-01 02:01
清晰视界等你来战！EVNIA弈威携旗下旗舰电竞显示器亮相合肥师范
【ZOL中关村在线原创新闻】10月26日，“我们学校潮好玩第二季”落地合肥师范学院。知名显示器品牌飞利浦，带来了旗下的EVNIA弈威QD OLED双核电竞显示器...
10-25 06:51
Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock
Corcept Therapeutics (NASDAQ:CORT) underwent analysis by 6 analysts in the last...
10-20 22:03
Reported Sunday, Corcept Highlights ROSELLA Late-Breaker: Relacorilant Plus Nab-Paclitaxel Improves PFS And OS In Platinum-Resistant Ovarian Cancer
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker
10-20 15:37
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $145 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $145 price target.
10-10 19:06
Corcept Therapeutics Board Member Resigns, Continues as Consultant
An announcement from Corcept Therapeutics ( ($CORT) ) is now available. On Octo...
10-07 04:59
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
